Contrasting Tevogen Bio (TVGN) and Its Rivals

Tevogen Bio (NASDAQ:TVGN) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its rivals? We will compare Tevogen Bio to related companies based on the strength of its institutional ownership, profitability, earnings, risk, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of current recommendations for Tevogen Bio and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1	0	1	0	2.00
Tevogen Bio Competitors	5692	12140	37586	1156	2.60

Tevogen Bio presently has a consensus price target of $5.00, indicating a potential upside of 984.60%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 54.58%. Given Tevogen Bio’s higher probable upside, equities analysts plainly believe Tevogen Bio is more favorable than its rivals.

Earnings and Valuation

This table compares Tevogen Bio and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Tevogen Bio	N/A	-$13.73 million	-2.43
Tevogen Bio Competitors	$972.75 million	-$45.42 million	11.76

Tevogen Bio’s rivals have higher revenue, but lower earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 73.2% of Tevogen Bio shares are owned by company insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Tevogen Bio has a beta of -0.86, meaning that its share price is 186% less volatile than the S&P 500. Comparatively, Tevogen Bio’s rivals have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.

Profitability

This table compares Tevogen Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-761.89%
Tevogen Bio Competitors	-1,425.99%	-589.65%	-28.81%

Summary

Tevogen Bio rivals beat Tevogen Bio on 8 of the 13 factors compared.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.